The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates.

Cancer Drug Resist · 2023 · PMC10099594 · PMID 37065870

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantP = 7.8 × 10 -22actually significant

The median follow-up for T-DXd was 16.2 months; the median PFS was 6.8 months for the T-DM1 groups, while the median PFS had not been reached for the T-DXd group, with a highly significant difference (HR of 0.28, 0.22-0.37, P = 7.8 × 10 -22 ).

also in 23,678 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.